Search Results

You are looking at 1 - 10 of 87 items for :

  • "prostate-specific antigen (PSA)" x
Clear All
Full access

Eli Rosenbaum, Alan Partin and Mario A. Eisenberger

experience . Int J Radiat Oncol Biol Phys 2003 ; 57 : 944 – 952 . 6 Lotan Y Roehrborn CG . Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians .. Prostate Cancer Prostatic

Full access

Brandon A. Mahal, Ming-Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff and Anthony V. D'Amico

deprivation therapy (ADT) are often curative treatments for localized disease, 2 – 5 approximately one-quarter of patients will experience recurrence within 10 years after curative-intent therapy. 6 , 7 An increasing prostate-specific antigen (PSA) level

Full access

Nicolas Batty, Naveen Yarlagadda and Roberto Pili

prednisone. Case Report A 43-year-old man noted urinary frequency and hesitancy, with incomplete voiding. His prostate-specific antigen (PSA) level was 387 ng/mL ( Figure 1 ). A transrectal ultrasound revealed an enlarged prostate gland

Full access

Peter H. Carroll and James L. Mohler

-risk patients is not completely known,” Dr. Carroll stated. A key feature of the updated guidelines is that they provide alternatives to routine biopsy in men with elevated prostate-specific antigen (PSA) levels, such as serum biomarker testing and parametric

Full access

Stacy Loeb and H. Ballentine Carter

Although prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce metastases and mortality from prostate cancer, 1 , 2 its use has numerous drawbacks. A key issue is its limited specificity for clinically

Full access

Michelle L. McDonald and J. Kellogg Parsons

part to lead time bias after earlier detection through widespread use of prostate-specific antigen (PSA) testing, this trend has also largely been attributed to the treatment of screen-detected tumors. 2 – 4 Randomized trials have since confirmed the

Full access

Mark L. Gonzalgo and H. Ballentine Carter

. Ross KS Carter HB Pearson JD . Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection . JAMA 2000 ; 284 : 1399 – 1405 . 24. Prostate-specific antigen (PSA) best practice policy. American

Full access

Peter R. Carroll and Andrew J. Vickers

center of the debate is the question of whether the benefits of prostate-specific antigen (PSA) screening (namely the reduction in mortality) outweigh the harms (overdiagnosis and overtreatment). According to Dr. Vickers and his colleague Peter R. Carroll

Full access

William J. Catalona and Stacy Loeb

T he prostate-specific antigen (PSA) blood test is the foundation for modern prostate cancer (CaP) screening. Initially it was used in forensic medicine. The subsequent discovery that it could be measured in serum, and that serum levels increase

Full access

Devon C. Snow and Eric A. Klein

available for metastatic prostate cancer, treatment can be curative if it is caught early. The goal of early diagnosis and radical treatment was first suggested in 1905. 2 The introduction of prostate-specific antigen (PSA) as a screening tool in the late